Pacira's EXPAREL Patent Status and Exclusivity
Pacira Biosciences' EXPAREL (bupivacaine liposome injectable suspension) has faced multiple patent challenges, impacting its market exclusivity. The foundational U.S. Patent No. 7,238,715, which covers the extended-release formulation of bupivacaine, has been a significant point of contention.
When Does EXPAREL Patent Exclusivity End?
While the primary patent for EXPAREL, U.S. Patent No. 7,238,715, has an original expiration date of 2026, its actual market exclusivity has been subject to legal challenges. These challenges have the potential to alter the landscape of generic competition and market access. DrugPatentWatch.com tracks these patent statuses and litigation details.
Why Are Companies Challenging EXPAREL Patents?
Generic drug manufacturers typically challenge patents to pave the way for their own versions of a drug to enter the market. Successful patent challenges can lead to earlier market entry for generics, increasing competition and potentially lowering drug prices. For EXPAREL, these challenges focus on the validity and scope of its core patents.
What Patents Cover EXPAREL?
Beyond the primary patent, U.S. Patent No. 7,238,715, there are other patents associated with EXPAREL, including those related to its manufacturing and specific indications. These additional patents can also influence the duration of market exclusivity.
How Does EXPAREL Compare to Other Pain Management Options?
EXPAREL is a non-opioid analgesic designed for postsurgical pain management. It utilizes proprietary DepoFoam technology to provide extended release of bupivacaine, aiming to reduce the need for opioids and potentially lower the incidence of opioid-related side effects. Its mechanism involves encapsulating the anesthetic in lipid-based particles that gradually release the drug over time.
Can Biosimilars or Generics Enter Before Patent Expiry?
The entry of generic versions of EXPAREL is directly tied to the outcome of patent litigation. If patents are successfully invalidated or found to be not infringed, generic manufacturers may be able to launch their products before the original patent expiry. The regulatory pathway for generics differs from that of biosimilars, which apply to biologic drugs.
What is the Litigation Status for EXPAREL Patents?
EXPAREL's patents have been involved in inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO) and subsequent litigation in federal courts. These legal battles determine the enforceability of the patents and influence the timeline for generic market entry.
What Risks Are Associated with EXPAREL?
As with any medication, EXPAREL carries potential risks and side effects. These can include localized reactions at the injection site and systemic effects related to the anesthetic. Patient concerns and physician prescribing practices are influenced by the drug's efficacy, safety profile, and cost.
Who Are the Competitors in the Postsurgical Pain Market?
The postsurgical pain management market is competitive, with various analgesic options available, including opioids, NSAIDs, and other local anesthetics. Pacira Biosciences faces competition from other pharmaceutical companies offering alternative pain relief solutions.
Sources:
[1] DrugPatentWatch.com